American Society of Clinical Oncology Annual Meeting (ASCO) | Conference

Howard A. Burris, MD, Talks QOL With Durvalumab/Chemo in Advanced Biliary Tract Cancer From TOPAZ-1 Trial
July 13, 2022

Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes data that were presented at 2022 ASCO.

Larotrectinib Trial Yields Promising Real-World Findings in TRK Fusion–Positive Disease
July 05, 2022

Patients with TRK fusion–positive disease experienced promising survival outcomes following treatment with larotrectinib vs standard of care.

Shubham Pant, MD, Highlights the Potential of ELI-002 2P to Treat MRD in KRAS-Mutant Solid Malignancies
July 04, 2022

Shubham Pant, MD, spoke to the potential of ELI-002 2P as a treatment for minimal residual disease positivity in patients with KRAS-mutant solid tumors.

Benjamin Cooper, MD, Remarks on Future Analyses of TAK-676 Plus Pembrolizumab in Solid Tumors Undergoing Radiation
July 03, 2022

Benjamin Cooper, MD, discussed potential future studies exploring TAK-676 plus pembrolizumab after radiation for those with solid tumors.

Long-Term Follow-Up Spotlights Ongoing Positive Outcomes With Selpercatinib in RET Fusion–Positive Cancers
July 02, 2022

Patients with RET fusion–positive solid tumors continued to experience benefit from treatment with selpercatinib, according to extended follow-up from the phase 1/2 LIBRETTO-001 basket study.

Benjamin Cooper, MD, Examines Rationale Behind Combining TAK-676 With Pembrolizumab After Radiation in Select Solid Tumors
June 27, 2022

Benjamin Cooper, MD, discussed an ongoing trial examining TAK-676 in combination with pembrolizumab after radiation therapy for patients with non–small cell lung cancer, head and neck cancer, and triple-negative breast cancer.

Frontline Tislelizumab/Chemo Bests Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer
June 11, 2022

Results of the phase 3 RATIONALE-309 trial demonstrate efficacy of tislelizumab added to chemotherapy for recurrent or metastatic nasopharyngeal carcinoma.

Activity of Rivoceranib in Adenoid Cystic Carcinoma Showcased at ASCO 2022
June 11, 2022

Treatment with the oral VEGFR2 inhibitor rivoceranib appears to induce responses in recurrent or metastatic adenoid cystic carcinoma.

Seribantumab Leads to Promising Efficacy in Solid Tumors with NRG1 Fusions
June 10, 2022

Results from the phase 2 CRESTONE trial showed positive overall response rates in patients with solid tumors harboring NRG1 fusions treated with seribantumab monotherapy.

Advanced Solid Tumors Respond to SOT101 With or Without Pembrolizumab
June 08, 2022

A phase 1 trial evaluating SOT101 plus or minus pembrolizumab indicates the safety and potential efficacy of the agent for the treatment of advanced solid tumors.